The Global Threat of Antibiotic Resistance

Pharmaceutical companies that produce antibiotics and vaccines may see an increased demand and focus as global health efforts prioritize accessibility; companies like Pfizer could benefit positively from this shift. Additionally, companies involved in health infrastructure in developing regions may also gain. However, antibiotic manufacturers might face scrutiny if they cannot balance production and responsible use, which could challenge their standing.

Investors should also consider healthcare ETFs such as the Health Care Select Sector SPDR Fund (XLV), which could see a positive impact as overall public health spending rises in response to global health initiatives.